4th Quarter - Amendment

GOVERNMENT COUNSEL, LLC for APOTEX CORPORATION

Firm
Client
Income
$20,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 13, 2025 $20,000 Replaced
4th Quarter - Amendment (this page) Jan 22, 2025 $20,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Federal policy relating to strengthening domestic generic production and market access barriers for generic pharmaceuticals.

Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.

LobbyistCovered position, as disclosed
HENRY W MENN Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Defense DEF

S. 4638- National Defense Authorization Act for Fiscal Year 2025 (NDAA) relating to generic drug procurement.

Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.

LobbyistCovered position, as disclosed
HENRY W MENN Chief of Staff, Sen. Bob Graham; Minority Staff Director & Counsel, Sen. Cmte on Veterans Affairs; Sp. Asst. Legislative Affairs, FDA Office of Commissioner.

Contacted: SENATE

Bills named: S. 4638 (118th)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
APOTEX INC. Canada Canada — —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.